From "only low prices" to "stability in clinical practices", centralized procurement has begun to address the issue of "internal competition".

The 12th batch of national organized drug centralized volume procurement work has recently started, and it is expected to organize the opening of bids in the near future. Data shows that the previous 11 batches of national organized drug centralized procurement have covered over 490 varieties of drugs, while this batch of centralized procurement has selected 65 types of drugs. Since the start of the 11th batch of centralized procurement last year, the National Medical Insurance Administration has proposed the principles of "stabilizing clinical use, ensuring quality, preventing collusion, and preventing internal circulation". These four principles are also clearly reflected in the reporting requirements of the 12th batch of centralized procurement.